Literature DB >> 7127905

Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.

A Vincent, J Newsom-Davis.   

Abstract

Anti-acetylcholine receptor (anti-AChR) antibody characteristics including light chain, IgG subclass, avidity for denervated human acetylcholine receptor and reaction with various human and mammalian AChR preparations were examined in 11 patients who developed myasthenia during penicillamine treatment of rheumatoid arthritis. Results were compared with those already reported in 35 patients with generalized idiopathic myasthenia gravis (MG). We found significant differences in the avidity and the light chain of the anti-AChR. However, anti-AChR characteristics in 12 patients with recent onset (less than 4 months' duration) idiopathic MG did not differ significantly from those in patients with penicillamine-induced MG. In the patients with generalized MG a trend was found towards higher percentage of kappa light chain and higher anti-AChR avidity with duration of disease. Anti-acetylcholine receptor antibodies in penicillamine-induced myasthenia gravis therefore appear to be similar to those of idiopathic myasthenia gravis of recent onset.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7127905      PMCID: PMC1536490     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Anti-acetycholine receptor antibodies in penicillamine treated patients without myasthenia gravis.

Authors:  V M Martin; A Vincent; C Clarke
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

2.  Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis.

Authors:  R C Bucknall; G Balint; R L Dawkins
Journal:  Scand J Rheumatol Suppl       Date:  1979

3.  The determination of serum immunoglobulin concentrations on the basis of their light-chain antigenic properties.

Authors:  K Eickhoff; R Heipertz
Journal:  Clin Chim Acta       Date:  1977-07-15       Impact factor: 3.786

4.  Properties and serum levels of specific populations of anti-acetylcholine receptor antibodies in myasthenia gravis.

Authors:  B W Fulpius; A K Lefvert; S Cuénoud; A Mourey
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  Autoantibodies and HLA antigens in ocular, generalized and penicillamine-induced myasthenia gravis.

Authors:  R L Dawkins; F T Christiansen; M J Garlepp
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

6.  Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis.

Authors:  A Vincent; J Newsom-Davis; V Martin
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

7.  Effects of D-penicillamine on neuromuscular transmission in rats.

Authors:  M S Aldrich; Y I Kim; D B Sanders
Journal:  Muscle Nerve       Date:  1979 May-Jun       Impact factor: 3.217

8.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

9.  Specificities of antibodies to acetylcholine receptors.

Authors:  J Lindstrom; M Campbell; B Nave
Journal:  Muscle Nerve       Date:  1978 Mar-Apr       Impact factor: 3.217

  9 in total
  11 in total

Review 1.  Immunopathogenesis and treatment of myasthenia gravis.

Authors:  A I Levinson; B Zweiman; R P Lisak
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

2.  Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis.

Authors:  S J Tzartos; E Morel; A Efthimiadis; A F Bustarret; J D'Anglejan; A A Drosos; H A Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

3.  Binding and blocking antibodies to the human acetylcholine receptor: are they selected in various myasthenia gravis forms?

Authors:  E Morel; B Vernet-der Garabedian; B Eymard; F Raimond; F A Bustarret; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  HLA antigens in penicillamine induced myasthenia gravis.

Authors:  A Vincent; J Newsom-Davis
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-12

5.  HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

Authors:  M I Garlepp; R L Dawkins; F T Christiansen
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

6.  Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

Review 7.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

9.  HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

Authors:  M J Garlepp; R L Dawkins; F T Christiansen
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

10.  Clinical implementation of anti-acetylcholine receptor antibodies.

Authors:  F E Somnier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.